Forecasting the Future of Cardiovascular Disease in the United States
Прогнозирование будущего сердечно-сосудистых заболеваний в Соединённых Штатах
2011-01-25
SCID: 54.1/82ag7kxb
Discuss with AI
American Heart Association cost projection methodologyCVD prevalence projection 2010–2030cardiovascular disease (CVD)direct medical costs (2008$)indirect costs due to lost productivity
Figures from the paper
Abstract (AI)
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. METHODS AND RESULTS: To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. CONCLUSIONS: These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.
Key Findings
1
By 2030, 40.5% of the US population is projected to have some form of cardiovascular disease (CVD).
2
Conclusion: Without effective prevention strategies, CVD prevalence and associated costs are projected to increase substantially.
3
Real (2008$) total direct medical costs of CVD are projected to triple from $273 billion in 2010 to $818 billion in 2030.
4
Real indirect costs due to lost productivity for all CVD are projected to increase from $172 billion in 2010 to $276 billion in 2030, a 61% increase.
5
The American Heart Association developed a projection methodology for hypertension, coronary heart disease, heart failure, stroke, and other CVD that avoids double counting patients with multiple conditions.
Research Object
Cardiovascular disease burden in the United States (prevalence and costs for hypertension, coronary heart disease, heart failure, stroke, and other CVD) from 2010 to 2030
Research Subject
Projected future prevalence and economic burden (direct medical costs and indirect productivity costs) of cardiovascular disease and its major components between 2010 and 2030
Publication Details
Publication Date
2011-01-25
Journal
Publisher
ISSN
Cited by
3207
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by11
2013 ACCF/AHA Guideline for the Management of Heart Failure2013
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
European guidelines on cardiovascular disease prevention in clinical practice: executive summary2007
Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association2013
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 22015
Environmental Determinants of Cardiovascular Disease2017
Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity2015
2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines2022
Primary Prevention With Statins in the Elderly2018